Radioactive drug indicated for positron emission tomography (pet) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis
Active Awarded Last action
- Contract number
- 36C26123A0025
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Task orders
- 3 $2,017,346 obligated
Award facts
- Opportunity
-
- 36C26123Q0115 Solicitation number
- Combined order value
- $2,017,346 Current and potential, with all options
- Last date to order 76% complete
- IDV ceiling 37% used
- $5,500,000.00
- Maximum order
- $1,500,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a blanket purchase agreement and associated calls to Progenics Pharmaceuticals Inc. for the provision of radioactive drugs. The drugs are indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer and suspected metastasis.
Under the agreement, Progenics Pharmaceuticals received a call contract valued at $721,744 with a period of performance from October 2023 to September 2024. A separate call was awarded valued at $631,526 with a period of February 2023 to September 2023. Both calls utilize firm fixed pricing and will be performed in North Billerica, Massachusetts. The blanket purchase agreement has a potential value of $5.5 million and expires in December 2027.
The contracts aim to procure critical radioactive pharmaceuticals used in PET imaging to aid in the diagnosis and treatment of prostate cancer patients within the Veterans Health Administration. Timely access to such specialized drugs can improve outcomes for those suffering from this form of cancer.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36C26123A0025?
36C26123A0025 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 21 (Veterans Health Administration) on February 10, 2023.
How much is contract 36C26123A0025 worth?
Orders under 36C26123A0025 have obligated $2,017,346. 36C26123A0025's own ceiling is $5,500,000. A single order can be worth up to $1,500,000.
How many orders have been placed under contract 36C26123A0025?
3 orders have been placed under 36C26123A0025, the latest on October 1, 2024.
Who can order from contract 36C26123A0025?
36C26123A0025 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36C26123A0025 under another contract?
Yes. 36C26123A0025 is a blanket purchase agreement under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26123A0025 competed?
The extent of competition for 36C26123A0025 was full and open competition. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV